These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1170 related items for PubMed ID: 33963010

  • 1. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS.
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [Abstract] [Full Text] [Related]

  • 2. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T.
    JAMA Dermatol; 2020 Sep 01; 156(9):982-986. PubMed ID: 32667663
    [Abstract] [Full Text] [Related]

  • 7. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T.
    J Immunother Cancer; 2021 Feb 01; 9(2):. PubMed ID: 33563773
    [Abstract] [Full Text] [Related]

  • 8. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 9. [Not Available].
    Mateus C, Libenciuc C, Robert C.
    Bull Cancer; 2016 Jun 01; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [Abstract] [Full Text] [Related]

  • 10. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
    Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.
    JAMA Oncol; 2016 Feb 01; 2(2):234-40. PubMed ID: 26633184
    [Abstract] [Full Text] [Related]

  • 11. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
    Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.
    Ann Oncol; 2018 Jan 01; 29(1):250-255. PubMed ID: 29045547
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
    Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C.
    Cancer Immunol Immunother; 2019 Jul 01; 68(7):1171-1178. PubMed ID: 31172258
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carroll BT, Theuner J, Li S, Fu P, Kirkwood JM.
    JAMA Oncol; 2024 May 01; 10(5):612-620. PubMed ID: 38546551
    [Abstract] [Full Text] [Related]

  • 14. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, Lu-Yao G.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2136823. PubMed ID: 34854905
    [Abstract] [Full Text] [Related]

  • 15. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV.
    Lancet Oncol; 2021 Jun 01; 22(6):836-847. PubMed ID: 33989557
    [Abstract] [Full Text] [Related]

  • 16. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM.
    Eur J Cancer; 2019 Sep 01; 119():122-131. PubMed ID: 31442816
    [Abstract] [Full Text] [Related]

  • 17. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
    Patrinely JR, Baker LX, Davis EJ, Song H, Ye F, Johnson DB.
    Cancer; 2020 Aug 01; 126(15):3448-3455. PubMed ID: 32463489
    [Abstract] [Full Text] [Related]

  • 18. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R.
    Cancer; 2024 Sep 01; 130(17):2918-2927. PubMed ID: 38358334
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.